Cobimetinib
- Generic Name
- Cobimetinib
- Brand Names
- Cotellic
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21F3IN3O2
- CAS Number
- 934660-93-2
- Unique Ingredient Identifier
- ER29L26N1X
- Background
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metasta...
- Indication
Cobimetinib is indicated in combination with vemurafenib for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. As a single agent, cobimetinib is also indicated for the treatment of adult patients with histiocytic neoplasms.
- Associated Conditions
- Histiocytic Neoplasm, Metastatic Melanoma, Unresectable Melanoma
- Associated Therapies
- -
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT03175432
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT03139513
- Locations
- 🇫🇷
CH Metropole de Savoie, CHAMBERY Cedex, France
🇫🇷Hopital Louis Pasteur; Sce Dermatologie, Colmar, France
🇫🇷Hopital Cochin; Dermatologie, Paris, France
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
- Conditions
- Appendix AdenocarcinomaRare LesionSkin Squamous Cell CarcinomaMetastatic Malignant NeoplasmRare Neoplastic SyndromeLocally Advanced Skin Squamous Cell CarcinomaMetastatic Skin Squamous Cell CarcinomaMetastatic Small Intestinal AdenocarcinomaRefractory Malignant NeoplasmStage IV Small Intestinal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT03108131
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT03101254
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 514
- Registration Number
- NCT02908672
- Locations
- 🇺🇸
St. Luke's University Health network, Bethlehem, Pennsylvania, United States
🇫🇷Institut Gustave Roussy; Dermatologie, Villejuif, France
🇩🇪Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, Germany
Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- University Hospital, Essen
- Target Recruit Count
- 186
- Registration Number
- NCT02902029
- Locations
- 🇩🇪
HELIOS Klinikum Erfurt, Erfurt, Thuringia, Germany
🇩🇪Universitätsklinikum Schleswig-Holstein, Lübeck, Germany
🇩🇪University Hospital Essen, Department of Dermatology, Skin Cancer Center, Essen, North Rhine-Westphalia, Germany
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT02876224
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University Of Colorado, Aurora, Colorado, United States
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Yana Najjar
- Target Recruit Count
- 9
- Registration Number
- NCT02818023
- Locations
- 🇺🇸
UPMC Cancer Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
- Conditions
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 363
- Registration Number
- NCT02788279
- Locations
- 🇺🇸
Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists; SCRI, Fort Myers, Florida, United States
🇺🇸Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02768207
- Locations
- 🇧🇪
UZ Brussel, Brussel, Belgium
🇧🇪UZ Antwerpen, Edegem, Belgium
🇧🇪Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.